Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01616303
Title A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Quest PharmaTech Inc.

ovarian cancer


Carboplatin + Oregovomab + Paclitaxel

Carboplatin + Paclitaxel

Age Groups: adult
Covered Countries USA

No variant requirements are available.